CLOV Quote, Financials, Valuation and Earnings

Centene has a net margin of -6.56% compared to Clover Health Investments's net margin of 2.81%. Clover Health Investments's return on equity of -13.55% beat Centene's return on equity of 12.65%.

Clover Health Investments has a consensus price target of $4.69, signalling upside risk potential of 25%. On the other hand Centene has an analysts' consensus of $77.63 which suggests that it could grow by 24.37%. Given that Clover Health Investments has higher upside potential than Centene, analysts believe Clover Health Investments is more attractive than Centene.

Clover Health Investments has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Centene has a beta of 0.478, suggesting its less volatile than the S&P 500 by 52.18%.

Clover Health Investments has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Centene offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clover Health Investments pays -- of its earnings as a dividend. Centene pays out -- of its earnings as a dividend.

Clover Health Investments quarterly revenues are $337M, which are smaller than Centene quarterly revenues of $46.6B. Clover Health Investments's net income of -$22.1M is lower than Centene's net income of $1.3B. Notably, Clover Health Investments's price-to-earnings ratio is -- while Centene's PE ratio is 9.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments is 1.40x versus 0.19x for Centene. Usually stocks with elevated PS ratios are considered overvalued.

Elevance Health has a net margin of -6.56% compared to Clover Health Investments's net margin of 4.47%. Clover Health Investments's return on equity of -13.55% beat Elevance Health's return on equity of 14.03%.

Clover Health Investments has a consensus price target of $4.69, signalling upside risk potential of 25%. On the other hand Elevance Health has an analysts' consensus of $505.55 which suggests that it could grow by 22.59%. Given that Clover Health Investments has higher upside potential than Elevance Health, analysts believe Clover Health Investments is more attractive than Elevance Health.

Clover Health Investments has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Elevance Health has a beta of 0.657, suggesting its less volatile than the S&P 500 by 34.296%.

Clover Health Investments has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Elevance Health offers a yield of 1.6% to investors and pays a quarterly dividend of $1.71 per share. Clover Health Investments pays -- of its earnings as a dividend. Elevance Health pays out 25.22% of its earnings as a dividend. Elevance Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Clover Health Investments quarterly revenues are $337M, which are smaller than Elevance Health quarterly revenues of $48.9B. Clover Health Investments's net income of -$22.1M is lower than Elevance Health's net income of $2.2B. Notably, Clover Health Investments's price-to-earnings ratio is -- while Elevance Health's PE ratio is 16.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments is 1.40x versus 0.52x for Elevance Health. Usually stocks with elevated PS ratios are considered overvalued.

Oscar Health has a net margin of -6.56% compared to Clover Health Investments's net margin of 9.04%. Clover Health Investments's return on equity of -13.55% beat Oscar Health's return on equity of 10.83%.

Clover Health Investments has a consensus price target of $4.69, signalling upside risk potential of 25%. On the other hand Oscar Health has an analysts' consensus of $19.36 which suggests that it could grow by 13.47%. Given that Clover Health Investments has higher upside potential than Oscar Health, analysts believe Clover Health Investments is more attractive than Oscar Health.

Clover Health Investments has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oscar Health has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Clover Health Investments has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oscar Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clover Health Investments pays -- of its earnings as a dividend. Oscar Health pays out -- of its earnings as a dividend.

Clover Health Investments quarterly revenues are $337M, which are smaller than Oscar Health quarterly revenues of $3B. Clover Health Investments's net income of -$22.1M is lower than Oscar Health's net income of $275.3M. Notably, Clover Health Investments's price-to-earnings ratio is -- while Oscar Health's PE ratio is 60.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments is 1.40x versus 0.47x for Oscar Health. Usually stocks with elevated PS ratios are considered overvalued.

Progyny has a net margin of -6.56% compared to Clover Health Investments's net margin of 3.53%. Clover Health Investments's return on equity of -13.55% beat Progyny's return on equity of 11.14%.

Clover Health Investments has a consensus price target of $4.69, signalling upside risk potential of 25%. On the other hand Progyny has an analysts' consensus of $26.75 which suggests that it could grow by 14.46%. Given that Clover Health Investments has higher upside potential than Progyny, analysts believe Clover Health Investments is more attractive than Progyny.

Clover Health Investments has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Progyny has a beta of 1.372, suggesting its more volatile than the S&P 500 by 37.195%.

Clover Health Investments has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Progyny offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clover Health Investments pays -- of its earnings as a dividend. Progyny pays out -- of its earnings as a dividend.

Clover Health Investments quarterly revenues are $337M, which are larger than Progyny quarterly revenues of $298.4M. Clover Health Investments's net income of -$22.1M is lower than Progyny's net income of $10.5M. Notably, Clover Health Investments's price-to-earnings ratio is -- while Progyny's PE ratio is 41.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clover Health Investments is 1.40x versus 1.94x for Progyny. Usually stocks with elevated PS ratios are considered overvalued.